Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Cholinesterase Inhibitors

Criteria

Inclusion Criteria:

• Patient has mild to moderate Alzheimer's disease

• Patient has been receiving a stable dose of an acetylcholinesterase inhibitor

• Patient has a MMSE score between 12 and 26

• Patient has a MHIS score of less than or equal to 4

• Females must be postmenopausal for at least two years or surgically sterile

• Patient has an identified, reliable, caregiver who will support him/her to ensure compliance with treatment and will accompany them to each outpatient visit

Exclusion Criteria:

• Patient is living in a nursing home

• Patient has a history of any significant neurologic disease other than Alzheimer's disease

• Patient has any uncontrolled medical illness

• Patient uses non-prescribed drugs of abuse or has a history of drug or alcohol abuse/dependence